# BREAKWATER (NCT04607421)

> A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04607421
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Pfizer
- Conditions: Neoplasms
- Interventions: Encorafenib; Cetuximab; Oxaliplatin; Irinotecan; Leucovorin; 5-FU; Capecitabine; Bevacizumab
- Enrollment: 841
- Primary outcome: SLI: Number of Participants With Dose Limiting Toxicity (DLTs)
- Primary outcome: Phase 3: Progression Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) for Arm B vs Arm C - FAS
- Primary outcome: Phase 3: Objective Response Rate (ORR) as Assessed by BICR for Arm B vs Arm C - FAS ORR Subset
- Primary outcome: Cohort 3: ORR as Assessed by BICR for Arm D vs Arm E - FAS

## Questions raised in the commentary

_Automated from the 40 newest of 399 indexed sources (Jun 2026 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether chemotherapy adds value to encorafenib and cetuximab
- Which biomarkers identify patients most likely to benefit
- Whether immunotherapy or BREAKWATER is preferable for MSI-high BRAF-mutant disease

## Indexed commentary on BREAKWATER so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 214
- YouTube: 102
- Podcasts: 73
- X videos: 7
- Bluesky threads: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=breakwater-nct04607421

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04607421", "email": "<work email>"}; the inbox owner confirms by the emailed link.